Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: tewdwr who wrote (944)	6/7/1999 3:43:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 965

The GNE/Roche deal is good news for CNTO relating to the Retavase litigation. From CNTO's 10-K: In the event the governance agreement between Roche Healthcare's parent and Genentech allows Roche Healthcare's parent to control Genentech or in the event the parent obtains 100% of the stock of Genentech, Roche Healthcare's parent will cause the patent litigation to be dismissed with prejudice and will cause Genentech not to institute any additional infringement litigation relating to RETAVASE. The Remicade RA news today is also excellent, putting many of the safety concerns to rest. The activase/ReoPro news from a few days ago confirms my feeling that this combo (and of course the Retavase/Reopro combo) is going to be very significant. So lots of positive developments quite aside from any takeover rumors. Clearly the cheapest of the second tiers. Peter